A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-06

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase II single-center study to evaluate the safety and effectiveness of vibecotamab, a CD3-CD123 bispecific antibody, in patients with acute myeloid leukemia with persistent or recurrent measurable residual disease and in patients with myelodysplastic syndrome that has not responded to or relapsed after conventional therapy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

NCT07270978

Acute Myeloid Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasm

RECRUITING PHASE1

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

NCT02003573

Leukemia, Myeloid, Acute

TERMINATED PHASE1

Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

NCT01550224

Acute Myeloid Leukemia With 11q23-abnormality in Relapse

COMPLETED PHASE2

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

NCT00002818

Drug/Agent Toxicity by Tissue/Organ Leukemia Lymphoma +1 more

COMPLETED PHASE1

Nivolumab in AML in Remission at High Risk for Relapse

NCT02532231

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Adult Acute Myeloid Leukemia in Remission Blasts Under 10 Percent of Bone Marrow Nucleated Cells +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objectives:

* AML MRD cohort: To determine the MRD negativity rate after 4 cycles of vibecotamab in patients with AML with MRD
* MDS post-HMA cohort: To determine the response rate (defined as CR + marrow CR \[mCR\] + partial remission \[PR\] + hematologic improvement \[HI\]) after 4 cycles of vibecotamab in patients with MDS after HMA failure

Secondary Objectives:

* To assess other efficacy endpoints, including remission duration, duration of MRD response (AML MRD arm only), CR rate (MDS arm only), relapse-free survival, overall survival
* To assess the safety of vibecotamab in patients with AML with MRD and in patients with MDS post-HMA failure

Exploratory Objectives:

* To correlate clinical outcomes with CD123 expression
* To determine the CD123 expression in patients who relapse after vibecotamab therapy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AML MDS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AML MRD cohort only

Each study cycle is 28 days. Vibecotamab by vein (IV) over about 2 hours On Days 1, 3, 5, 8, 15 and 22 of Cycle 1 and then on Days 1, 8, 15 and 22 of Cycles 2-4.

Group Type EXPERIMENTAL

Vibecotamab

Intervention Type DRUG

Given by vein (IV)

Dexamethasone

Intervention Type DRUG

Given by vein (IV) over about 60 minutes before the dose

Acetaminophen

Intervention Type DRUG

Given by mouth (PO) about 30-60 minutes before the dose

Diphenhydramine

Intervention Type DRUG

Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose

MDS post-HMA failure cohort only

Each study cycle is 28 days. Vibecotamab by vein (IV) over about 2 hours On Days 1, 3, 5, 8, 15 and 22 of Cycle 1 and then on Days 1, 8, 15 and 22 of Cycles 2-4.

Group Type EXPERIMENTAL

Vibecotamab

Intervention Type DRUG

Given by vein (IV)

Dexamethasone

Intervention Type DRUG

Given by vein (IV) over about 60 minutes before the dose

Acetaminophen

Intervention Type DRUG

Given by mouth (PO) about 30-60 minutes before the dose

Diphenhydramine

Intervention Type DRUG

Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vibecotamab

Given by vein (IV)

Intervention Type DRUG

Dexamethasone

Given by vein (IV) over about 60 minutes before the dose

Intervention Type DRUG

Acetaminophen

Given by mouth (PO) about 30-60 minutes before the dose

Intervention Type DRUG

Diphenhydramine

Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

XmAb14045 Decadron TylenolÂ® DorcolÂ® Feverallâ"¢ PanadolÂ® APAP N-Acetyl-P-Aminophenol Paracetamol Ofirmevâ"¢ BenadrylÂ®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults ≥18 years of age
2. AML MRD cohort only: AML in first or second morphologic remission (defined as complete remission \[CR\], complete remission with incomplete hematologic recovery \[CRi\], or morphologic leukemia-free state \[MLFS\]) who have received a minimum prior therapy with at least 1 course of intensive intermediate to high-cytarabine-based chemotherapy or at least 2 courses of lower-intensity therapy (e.g. hypomethylating agent or low-dose cytarabine-based)
3. AML MRD cohort only: Persistent or recurrent MRD positivity detected by MFC at a level of ≥0.1%.
4. AML MRD cohort only: For patients who are MRD positive by MFC, residual leukemia must be positive for CD123 expression at a level of at least 20% (as assessed by clinical pathologist)
5. MDS post-HMA failure cohort only: MDS that is intermediate, high risk or very high risk by the Revised International Prognostic Scoring System (IPSS) or CMML-1 or CMML-2 who have not responded after at least 4 cycles of azacitidine and/or decitabine or who progressed or relapsed after azacitidine and/or decitabine, regardless of the number of cycles received
6. MDS post-HMA failure cohort only: Aberrant blasts must be positive for CD123 expression by MFC at a level of at least 20% (as assessed by clinical pathologist)
7. Performance status 2 (ECOG Scale).
8. Female patients of childbearing potential must agree to use a highly effective method of birth control during and for 4 weeks after the last dose of vibecotamab and must also refrain from oocyte donation during this time period. Women are considered to be of childbearing potential unless it is documented that they are over the age of 60 OR postmenopausal by history with no menses for 1 year and confirmed by follicle-stimulating hormone (using local reference ranges) OR have a history of hysterectomy and/or bilateral oophorectomy OR have a history of bilateral tubal ligation. Highly effective methods of birth control include hormonal birth control (oral, intravaginal, transdermal, implantable, or intrauterine), intrauterine devices, vasectomized partner, or any double-barrier methods (combination of male condom and spermicide with either cap, diaphragm, or sponge).
9. Male patients and their female partner of childbearing potential must agree to use highly effective contraception, as above, and refrain from donating sperm during the treatment period and for at least 4 weeks after the last dose of vibecotamab.
10. Signed informed consent

Exclusion Criteria

1. Prior treatment with vibecotamab or anti-CD123-directed therapy.
2. Clinically significant organ dysfunction, defined as:

1. AST or ALT \>3x the upper limit of normal (ULN)
2. Total bilirubin \>1.5x the ULN, unless due to ongoing hemolysis or Gilbert's syndrome
3. Creatinine clearance \<30 mL/min
4. Active Grade III-V cardiac failure as defined by the New York Heart Association Criteria.
3. Active serious infection not controlled by oral or intravenous antibiotics (e.g. persistent fever or lack of clinical improvement despite antimicrobial treatment).
4. Patients who are expected to be able to proceed with stem cell transplantation within the next 30 days
5. Known human immunodeficiency virus (HIV) with detectable viral load.
6. Known hepatitis B surface antigen seropositive or known or suspected active hepatitis C infection Note: Patients who have isolated positive hepatitis B core antibody (ie, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Patients who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load.
7. Patients with a prior or concurrent malignancy whose natural history or treatment is not anticipated to interfere with the safety or efficacy assessment of the investigational regimen may be included only after discussion with the PI
8. Treatment with any antileukemic agents or chemotherapy agents in the last 7 days or 5 half-lives (whichever is sooner) before study entry

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No